Proprietary Affibody® molecules and Albumod platforms. Lead candidate is an IL-17 with positive Ph2 12wk data in psoriasis. Also has a Ph1 FcRn for b-cell autoimmune diseases partnered with ALXN. Revenue generating from earlier licensed assets. Backed by Investor AB.
Phase l or ll
Autoimmune, Dermatology, Oncology, Rare Disease
Antibodies, Platform Technology
Gunnar Asplunds Allé 24, SE-171 69
Stockholm, Stockholms Lan 17169
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.